INTRODUCTION
Bullous pemphigoid (BP) is an autoimmune subepidermal blistering disease. 1 In patients with BP, autoantibodies occur against the hemidesmosomal BP230 and BP180 glycoprotein in the basal membrane. It is characterized by pruritic urticarial plaques and tense bullae localized to the trunk and flexural areas of the extremities. 2, 3 Bullous pemphigoid mostly affects elderly people and rarely occurs in people younger than 50 years of age. 4 Patients with BP represent an elevated expression of various cytokines and eosinophil activation resulting an inflammatory process. 5 Recently an association between BP and neurological disorders have been reported. 4 Also, there has been speculation of a potential thrombotic risk in BP patients. 5 Mean platelet volume (MPV) correlates with platelet activation and it has been demonstrated that MPV is associated with inflammation. Therefore, it has been identified as a risk factor for for athero-thrombotic diseases. 6, 7 Neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) are the other systemic inflammation indicators that are used in state of chronic inflammatory diseases, including psoriasis. 8 In one study that researches MPV, it was shown that MPV values were significantly higher in the patient group compared to healthy control. In another study, NLR values were significantly higher in the patient group compared to the healthy controls. 9, 10 In this study, our aim was to evaluate the clinical, demographic characteristics, comorbid diseases and MPV, NLR, PLR values in patients with BP.
To our knowledge, there is no previous study in the literature researching NLR, PLR and MPV together in patients with BP.
MATERIAL AND METHODS

Patients
who received clinical and histopathological diagnosis of BP in Bolu Izzet Baysal Medical Faculty Dermatology Outpatient Clinic between 2008 and 2018 and age-and gender-matched control patients that were diagnosed with non-inflammatory dermatosis in the same clinic were enrolled into the study. We retrospectively screened the files of the subjects whom followed up for BP and controls in our clinic. Patients, whose clinic results were compatible but histopathology as incompatible with BP, were not be included in the study. The complete blood tests of the patients with BP were evaluated before the treatment period. Full blood counts for lymphocytes, neutrophils, platelets, NLR, PLR and MPV were recorded. The institutional ethics committee approved the study protocol with a reference number 2018/165. SPSS software was used for conduction of statistical analyses. SPSS was used for statistical analysis. Numbers and percentages used for descriptive statistics and for categorical variables and presented as mean, standard deviation, median, 25th percentile, 75th percentile, and minimum and maximum. Two-Sample Kolmogorov-Smirnov Test used for comparison of nonhomogenous parameters and t-test for homogenous variables. The chi-square test used for categorical variables. Statistical significance level set on a p value lower than 0.05.
RESULTS
Fourteen patients with BP (9 female, 5 male) and 14 control patients (9 female, 5 male) were included in the study. The mean age of the patient group and control group was 72 ± 15 years. There was no significant difference between the two groups in terms of gender and age (p=1, p=0.98; respectively).
Oral mucosal involvement was present in one of the cases (7,1%). Dermatologic examination revealed excoriations and erosions in nine patients (64,2%) and intact bullous lesions in five patients (35,7%).
In the patient group; seven patients were diagnosed with hypertension (50%), and four of these patients had coronary artery disease (28,5%) at the same time; five patient had diabetes mellitus (35,7%), one patient had cerebrovascular disease (7,1%), one patient had chronic obstructive pulmonary disease (7.14%), one had schizophrenia (7,14%), one had depression (7,1%) , one had asthma (7,1%), one had hyperthyroidism (7.1%) and one had cholelithiasis (7,1%).
Neutrophil counts were significantly higher in BP patients than the control group (p = 0.01). Lymphocyte counts were significantly lower in BP patients than the control group (p=0.042). The NLR of patients with BP was significantly higher than that of the control group (p = 0.01). There was no difference in platelet counts and PLR between the groups (p=0.91, p=0.06, respectively). There was no difference in MPV between groups (p=0.6). (Table 1 ) 
DISCUSSION
Bullous pemphigoid is an acquired bullous autoimmune dermatosis with an approximate annual incidence of 6 to 14 cases per 1 million population. It is primarily a disease of the geriatric population. 11 In accordance with this data, our patients' mean age was 72 ± 15 years. In 10-30% of the bullous pemphigoid cases, there is an involvement of the oral mucosa. (11) . In the studies of Akay et al. 3 , Ekiz et al. 12 and Yazıcı et al. 13 , 12,9%, ,17.2% and 28% of the patients had oral involvement, respectively. In our study the frequency of oral mucosal involvement (7.1%) is lower compared to the literature. This result may be related to the mild course of the clinical lesions of our cases.
In our study, the most common comorbid diseases in patients with BP were hypertension (50%), diabetes mellitus (35.7%) and coronary artery disease (28.5%), respectively. In the study of Tan et al. 14 , the frequency of hypertension in BP patients was 55%, diabetes mellitus was 32%, and ischemic heart disease was 33%. These frequencies were similar to our study. The most common comorbid diseases in the study of Kızılyel et al. 15 were diabetes mellitus (%7,9), hypertension (%7,9) and peptic ulcer (%7,9). In the study of Ekiz et al. 12 , BP was accompanied by diabetes (17,24%), vitiligo (3,4%), inflammatory bowel disease (3,4%) and coronary artery disease (3,4%). The high frequency of associated cardiovascular disease in our study may be due to the increased hypercoagulability in patients with BP. 5 The relationship between BP and malignancy is controversial and an English national record linkage study found no increased risk for malignant cancers in a cohort of people with a diagnosis of BP. 16 In our study, none of the patients had malignancy.
Autoreactive T cells play a critical role in the regulation of autoantibody production in BP. 17 Histopathological studies show that eosinophil-rich inflammatory infiltrate is found in blister formation. 18 Eosinophils are a source of tissue factor (TF), which is the initiator of blood coagulation. TF hypercoagulability may contribute to inflammation, tissue damage and later on formation of bullae in BP patients. 5 Several autoimmune disorders and some inflammatory dermatoses, such as lichen planus and psoriasis, have been reported in patients with BP, leading to the suspicion that the inflammatory process at the dermoepidermal junction in these diseases triggers autoimmunity against the target antigens of BP. 18 In BP, several cytokines such as IL-1α, IL-1β, IL-2, IL-5, IL-6, TNF-α and IFN-ɣ have been observed in blisters or serum. 19 Since the inflammatory process has been described in BP, cheap and practical markers are needed. NLR may be marker for inflammation in several diseases such as ankylosing spondylitis, familial Mediterranean fever, atherosclerosis, diabetes, malignancies, psoriasis and Behçet disease. [20] [21] [22] In the study of Uçmak et al., NLR values in patients with pemphigus vulgaris were significantly higher than that of the control group. 23 In the study of Ozer et al., patients with bullous pemphigoid, neutrophil count and NLR were found to be significantly higher in BP patients when compared to the controls. 10 In our study, NLR was found to be higher in BP patients when compared to the age and gender matched control patients. The result in our study may lead to the consideration that NLR might be a practical and cheap indicator of inflammation in BP.
MPV levels have been studied in several diseases, which included skin disorders, such as pemphigus vulgaris, psoriasis, Behçet's disease, and there are conflicting results in these studies. [24] [25] [26] In the study of Rifaioglu et al., MPV value in patients with BP was significantly higher than that of control subjects, but there was no association with disease severity and there was no significant difference between the MPV levels before and after the treatment. 9 In the study of Ozer et al.,there was no difference in MPV value between the patients with BP and the control group. 10 In our study, MPV levels were higher in the control group, but there was no significant difference between the two groups. This result suggests that MPV may not be a reliable indicator of inflammation in BP. PLR levels were found to be significantly higher in patients with atopic dermatitis, 27 psoriatic arthritis, 28 systemic lupus erythematosus. 29 In the study of Hayta et al. 30 , there was no difference in patients with pemphigus vulgaris and healthy controls in terms of PLR value. To our knowledge, there is no study investigating PLR value in patients with BP. In our study, there was no difference in PLR between the groups. In our study, the nonsignificant MPV and PLR levels in BP may be due to the comorbid diseases, which can frequently be accompanied by BP and can effect these values, were not excluded from the study in both patient and control groups.
Limitations of our study were the small number of patients, the fact that the measured markers were not repeated after treatment, the lack of autoimmune bullous skin disorder intensity score and the presence of patients with cardiovascular disorders and diabetes mellitus in the patient group. Systemic inflammatory diseases may alter inflammatory markers independent from bullous pemphigoid.
CONCLUSION
In conclusion, NLR may be an inexpensive and simple parameter of inflammation in patients with BP as stated in many studies. Our study is the first to evaluate three different inflammation markers such as NLR, MPV and PLR, easily obtained from full blood counts, together in BP patients which is a disease with inflammatory attributes. The results reported here need to be confirmed from long-term studies with larger patient groups.
